A carregar...
ATIM-26. INTERIM RESULTS OF THE EXTENSION PHASE OF A PHASE I/IIA TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM)
Cytomegalovirus (CMV) antigens have been reported in over 90% of GBM tumors. CD4(+)and CD8(+)T cells are most frequently directed against the gB and pp65 antigens, respectively, and are immunogenic targets in a CMV-based GBM vaccine. We have initiated a phase I/IIa clinical trial for patients with r...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6847368/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.025 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|